Nontuberculous Mycobacterial (NTM) Lung Infections

Insmed’s treatment-resistant lung disease drug gets FDA approval

Analysts, Black Box Warning, Chronic Lung Disease, COPD, FDA/Regulatory, Inflammation, Lung Disease, Nontuberculous Mycobacterial (NTM) Lung Infections

The Food and Drug Administration approved Insmed Inc.’s lead drug Arikayce to treat a rare chronic lung disease.

September 28, 2018/by Reuters Health

Insmed’s lung drug meets main goal in key study, shares soar

Lung Infections, Nontuberculous Mycobacterial (NTM) Lung Infections, Shares

Insmed Inc. said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading.

September 5, 2017/by Reuters Health